Gli-1 inhibitor program (NYU Langone Medical Center/ GliXogen),

N/A

Report date: 2025/01/15 13:53:40
NME

Base Information

Drug NameGli-1 inhibitor program (NYU Langone Medical Center/ GliXogen),
Drug Alias NameGANT-58GANT-61
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionZinc finger protein GLI1 inhibitors
TargetsZinc finger protein GLI1
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNyu Langone Health
China Registration ClassN/A

Develop Information

Active CompaniesGliXogen TherapeuticsNyu Langone Health
Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A